Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

Fluorouracil 25Oxaliplatin 24Irinotecan 24Leucovorin 23Bevacizumab 23Capecitabine 18Cetuximab 15Radiotherapy 6Gene Expression Profiling 5regorafenib 4Immunohistochemistry 4Gemcitabine 4Folfox protocol 4Colonoscopy 4Cisplatin 4Celecoxib 4Amplified Fragment Length Polymorphism Analysis 4Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Polymerase Chain Reaction 3Nivolumab 3Mitomycin 3Doxorubicin 3Cyclophosphamide 3Cholecalciferol 3Biopsy 3Aspirin 3sargramostim 2pembrolizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colonic Neoplasms × mirdametinib × Clear all
NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Pfizer

Phase 1/2 Terminated
79 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡